Marianne De Backer has been a strategist, scientist, business leader, deal maker and corporate investor in the healthcare industry for more than two decades. Her network cuts across pharmaceutical, biotech, tech, academia, VC, NGO, and government partners worldwide. She has been directly accountable for over two hundred strategic alliances in healthcare some of which have led to newly approved medicines now available to patients. Since 2019, she is a member of the Executive Committee, Executive Vice President and Head of Strategy, Business Development and Licensing of Bayer AG (BAYRY) Pharmaceuticals division. Marianne is spearheading the external growth agenda resulting in 26 new alliances and the acquisitions of Asklepios Biopharmaceutical and KaNDy Therapeutics in 2020. From 1991 through 2019, she was at Johnson & Johnson where she last held global Business and Corporate Development roles, including the position of Vice President of M&A Operations and Divestitures globally for the Pharmaceuticals Group and head of Infectious Diseases & Vaccines Business Development. Prior to that, she led a commercial business unit in Europe, launching two drugs in neuroscience and immunology. Marianne started her career in drug discovery research leading teams in both Europe and the United States. She serves as a non-executive Director on the Boards of Gladstone Foundation, Kronos Bio (KRON) and Arrowhead Pharmaceuticals (ARWR). Marianne holds an MBA from Erasmus University Rotterdam, The Netherlands; Master in Molecular Biology from Vrije Universitei, Brussels; Master in Engineering Biochemistry and a PhD in Biotechnology, both from Ghent University, Belgium.
Marianne De Backer, PhD
Head of Strategy, Business Development & Licensing, and Member of the Executive Committee, Bayer